Cargando…

Longitudinal immune profiles in type 1 leprosy reactions in Bangladesh, Brazil, Ethiopia and Nepal

BACKGROUND: Acute inflammatory reactions are a frequently occurring, tissue destructing phenomenon in infectious- as well as autoimmune diseases, providing clinical challenges for early diagnosis. In leprosy, an infectious disease initiated by Mycobacterium leprae (M. leprae), these reactions repres...

Descripción completa

Detalles Bibliográficos
Autores principales: Khadge, Saraswoti, Banu, Sayera, Bobosha, Kidist, van der Ploeg-van Schip, Jolien J., Goulart, Isabela M., Thapa, Pratibha, Kunwar, Chhatra B., van Meijgaarden, Krista E., van den Eeden, Susan J.F., Wilson, Louis, Kabir, Senjuti, Dey, Hymonti, Goulart, Luiz R., Lobato, Janaina, Carvalho, Washington, Bekele, Yonas, Franken, Kees L.M.C., Aseffa, Abraham, Spencer, John S., Oskam, Linda, Otttenhoff, Tom H.M., Hagge, Deanna A., Geluk, Annemieke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625471/
https://www.ncbi.nlm.nih.gov/pubmed/26510990
http://dx.doi.org/10.1186/s12879-015-1128-0
_version_ 1782397982370430976
author Khadge, Saraswoti
Banu, Sayera
Bobosha, Kidist
van der Ploeg-van Schip, Jolien J.
Goulart, Isabela M.
Thapa, Pratibha
Kunwar, Chhatra B.
van Meijgaarden, Krista E.
van den Eeden, Susan J.F.
Wilson, Louis
Kabir, Senjuti
Dey, Hymonti
Goulart, Luiz R.
Lobato, Janaina
Carvalho, Washington
Bekele, Yonas
Franken, Kees L.M.C.
Aseffa, Abraham
Spencer, John S.
Oskam, Linda
Otttenhoff, Tom H.M.
Hagge, Deanna A.
Geluk, Annemieke
author_facet Khadge, Saraswoti
Banu, Sayera
Bobosha, Kidist
van der Ploeg-van Schip, Jolien J.
Goulart, Isabela M.
Thapa, Pratibha
Kunwar, Chhatra B.
van Meijgaarden, Krista E.
van den Eeden, Susan J.F.
Wilson, Louis
Kabir, Senjuti
Dey, Hymonti
Goulart, Luiz R.
Lobato, Janaina
Carvalho, Washington
Bekele, Yonas
Franken, Kees L.M.C.
Aseffa, Abraham
Spencer, John S.
Oskam, Linda
Otttenhoff, Tom H.M.
Hagge, Deanna A.
Geluk, Annemieke
author_sort Khadge, Saraswoti
collection PubMed
description BACKGROUND: Acute inflammatory reactions are a frequently occurring, tissue destructing phenomenon in infectious- as well as autoimmune diseases, providing clinical challenges for early diagnosis. In leprosy, an infectious disease initiated by Mycobacterium leprae (M. leprae), these reactions represent the major cause of permanent neuropathy. However, laboratory tests for early diagnosis of reactional episodes which would significantly contribute to prevention of tissue damage are not yet available. Although classical diagnostics involve a variety of tests, current research utilizes limited approaches for biomarker identification. In this study, we therefore studied leprosy as a model to identify biomarkers specific for inflammatory reactional episodes. METHODS: To identify host biomarker profiles associated with early onset of type 1 leprosy reactions, prospective cohorts including leprosy patients with and without reactions were recruited in Bangladesh, Brazil, Ethiopia and Nepal. The presence of multiple cyto-/chemokines induced by M. leprae antigen stimulation of peripheral blood mononuclear cells as well as the levels of antibodies directed against M. leprae-specific antigens in sera, were measured longitudinally in patients. RESULTS: At all sites, longitudinal analyses showed that IFN-γ-, IP-10-, IL-17- and VEGF-production by M. leprae (antigen)-stimulated PBMC peaked at diagnosis of type 1 reactions, compared to when reactions were absent. In contrast, IL-10 production decreased during type 1 reaction while increasing after treatment. Thus, ratios of these pro-inflammatory cytokines versus IL-10 provide useful tools for early diagnosing type 1 reactions and evaluating treatment. Of further importance for rapid diagnosis, circulating IP-10 in sera were significantly increased during type 1 reactions. On the other hand, humoral immunity, characterized by M. leprae-specific antibody detection, did not identify onset of type 1 reactions, but allowed treatment monitoring instead. CONCLUSIONS: This study identifies immune-profiles as promising host biomarkers for detecting intra-individual changes during acute inflammation in leprosy, also providing an approach for other chronic (infectious) diseases to help early diagnose these episodes and contribute to timely treatment and prevention of tissue damage. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-015-1128-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4625471
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46254712015-10-30 Longitudinal immune profiles in type 1 leprosy reactions in Bangladesh, Brazil, Ethiopia and Nepal Khadge, Saraswoti Banu, Sayera Bobosha, Kidist van der Ploeg-van Schip, Jolien J. Goulart, Isabela M. Thapa, Pratibha Kunwar, Chhatra B. van Meijgaarden, Krista E. van den Eeden, Susan J.F. Wilson, Louis Kabir, Senjuti Dey, Hymonti Goulart, Luiz R. Lobato, Janaina Carvalho, Washington Bekele, Yonas Franken, Kees L.M.C. Aseffa, Abraham Spencer, John S. Oskam, Linda Otttenhoff, Tom H.M. Hagge, Deanna A. Geluk, Annemieke BMC Infect Dis Research Article BACKGROUND: Acute inflammatory reactions are a frequently occurring, tissue destructing phenomenon in infectious- as well as autoimmune diseases, providing clinical challenges for early diagnosis. In leprosy, an infectious disease initiated by Mycobacterium leprae (M. leprae), these reactions represent the major cause of permanent neuropathy. However, laboratory tests for early diagnosis of reactional episodes which would significantly contribute to prevention of tissue damage are not yet available. Although classical diagnostics involve a variety of tests, current research utilizes limited approaches for biomarker identification. In this study, we therefore studied leprosy as a model to identify biomarkers specific for inflammatory reactional episodes. METHODS: To identify host biomarker profiles associated with early onset of type 1 leprosy reactions, prospective cohorts including leprosy patients with and without reactions were recruited in Bangladesh, Brazil, Ethiopia and Nepal. The presence of multiple cyto-/chemokines induced by M. leprae antigen stimulation of peripheral blood mononuclear cells as well as the levels of antibodies directed against M. leprae-specific antigens in sera, were measured longitudinally in patients. RESULTS: At all sites, longitudinal analyses showed that IFN-γ-, IP-10-, IL-17- and VEGF-production by M. leprae (antigen)-stimulated PBMC peaked at diagnosis of type 1 reactions, compared to when reactions were absent. In contrast, IL-10 production decreased during type 1 reaction while increasing after treatment. Thus, ratios of these pro-inflammatory cytokines versus IL-10 provide useful tools for early diagnosing type 1 reactions and evaluating treatment. Of further importance for rapid diagnosis, circulating IP-10 in sera were significantly increased during type 1 reactions. On the other hand, humoral immunity, characterized by M. leprae-specific antibody detection, did not identify onset of type 1 reactions, but allowed treatment monitoring instead. CONCLUSIONS: This study identifies immune-profiles as promising host biomarkers for detecting intra-individual changes during acute inflammation in leprosy, also providing an approach for other chronic (infectious) diseases to help early diagnose these episodes and contribute to timely treatment and prevention of tissue damage. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-015-1128-0) contains supplementary material, which is available to authorized users. BioMed Central 2015-10-28 /pmc/articles/PMC4625471/ /pubmed/26510990 http://dx.doi.org/10.1186/s12879-015-1128-0 Text en © Khadge et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Khadge, Saraswoti
Banu, Sayera
Bobosha, Kidist
van der Ploeg-van Schip, Jolien J.
Goulart, Isabela M.
Thapa, Pratibha
Kunwar, Chhatra B.
van Meijgaarden, Krista E.
van den Eeden, Susan J.F.
Wilson, Louis
Kabir, Senjuti
Dey, Hymonti
Goulart, Luiz R.
Lobato, Janaina
Carvalho, Washington
Bekele, Yonas
Franken, Kees L.M.C.
Aseffa, Abraham
Spencer, John S.
Oskam, Linda
Otttenhoff, Tom H.M.
Hagge, Deanna A.
Geluk, Annemieke
Longitudinal immune profiles in type 1 leprosy reactions in Bangladesh, Brazil, Ethiopia and Nepal
title Longitudinal immune profiles in type 1 leprosy reactions in Bangladesh, Brazil, Ethiopia and Nepal
title_full Longitudinal immune profiles in type 1 leprosy reactions in Bangladesh, Brazil, Ethiopia and Nepal
title_fullStr Longitudinal immune profiles in type 1 leprosy reactions in Bangladesh, Brazil, Ethiopia and Nepal
title_full_unstemmed Longitudinal immune profiles in type 1 leprosy reactions in Bangladesh, Brazil, Ethiopia and Nepal
title_short Longitudinal immune profiles in type 1 leprosy reactions in Bangladesh, Brazil, Ethiopia and Nepal
title_sort longitudinal immune profiles in type 1 leprosy reactions in bangladesh, brazil, ethiopia and nepal
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625471/
https://www.ncbi.nlm.nih.gov/pubmed/26510990
http://dx.doi.org/10.1186/s12879-015-1128-0
work_keys_str_mv AT khadgesaraswoti longitudinalimmuneprofilesintype1leprosyreactionsinbangladeshbrazilethiopiaandnepal
AT banusayera longitudinalimmuneprofilesintype1leprosyreactionsinbangladeshbrazilethiopiaandnepal
AT boboshakidist longitudinalimmuneprofilesintype1leprosyreactionsinbangladeshbrazilethiopiaandnepal
AT vanderploegvanschipjolienj longitudinalimmuneprofilesintype1leprosyreactionsinbangladeshbrazilethiopiaandnepal
AT goulartisabelam longitudinalimmuneprofilesintype1leprosyreactionsinbangladeshbrazilethiopiaandnepal
AT thapapratibha longitudinalimmuneprofilesintype1leprosyreactionsinbangladeshbrazilethiopiaandnepal
AT kunwarchhatrab longitudinalimmuneprofilesintype1leprosyreactionsinbangladeshbrazilethiopiaandnepal
AT vanmeijgaardenkristae longitudinalimmuneprofilesintype1leprosyreactionsinbangladeshbrazilethiopiaandnepal
AT vandeneedensusanjf longitudinalimmuneprofilesintype1leprosyreactionsinbangladeshbrazilethiopiaandnepal
AT wilsonlouis longitudinalimmuneprofilesintype1leprosyreactionsinbangladeshbrazilethiopiaandnepal
AT kabirsenjuti longitudinalimmuneprofilesintype1leprosyreactionsinbangladeshbrazilethiopiaandnepal
AT deyhymonti longitudinalimmuneprofilesintype1leprosyreactionsinbangladeshbrazilethiopiaandnepal
AT goulartluizr longitudinalimmuneprofilesintype1leprosyreactionsinbangladeshbrazilethiopiaandnepal
AT lobatojanaina longitudinalimmuneprofilesintype1leprosyreactionsinbangladeshbrazilethiopiaandnepal
AT carvalhowashington longitudinalimmuneprofilesintype1leprosyreactionsinbangladeshbrazilethiopiaandnepal
AT bekeleyonas longitudinalimmuneprofilesintype1leprosyreactionsinbangladeshbrazilethiopiaandnepal
AT frankenkeeslmc longitudinalimmuneprofilesintype1leprosyreactionsinbangladeshbrazilethiopiaandnepal
AT aseffaabraham longitudinalimmuneprofilesintype1leprosyreactionsinbangladeshbrazilethiopiaandnepal
AT spencerjohns longitudinalimmuneprofilesintype1leprosyreactionsinbangladeshbrazilethiopiaandnepal
AT oskamlinda longitudinalimmuneprofilesintype1leprosyreactionsinbangladeshbrazilethiopiaandnepal
AT otttenhofftomhm longitudinalimmuneprofilesintype1leprosyreactionsinbangladeshbrazilethiopiaandnepal
AT haggedeannaa longitudinalimmuneprofilesintype1leprosyreactionsinbangladeshbrazilethiopiaandnepal
AT gelukannemieke longitudinalimmuneprofilesintype1leprosyreactionsinbangladeshbrazilethiopiaandnepal